| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-12-0489 |
| P8608 | Fatcat ID | release_kgtuzbtgszam3j4ch5sjfvseji |
| P698 | PubMed publication ID | 22529099 |
| P50 | author | Georg Gruenbacher | Q54269286 |
| P2093 | author name string | Martin Thurnher | |
| Oliver Nussbaumer | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3524-3531 | |
| P577 | publication date | 2012-04-23 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Novel aspects of mevalonate pathway inhibitors as antitumor agents | |
| P478 | volume | 18 |
| Q26774351 | A novel approach to the discovery of anti-tumor pharmaceuticals: searching for activators of liponecrosis |
| Q41593086 | A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer |
| Q36907149 | Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells |
| Q46416599 | Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid |
| Q38840434 | Annexin A1 is involved in the acquisition and maintenance of a stem cell-like/aggressive phenotype in prostate cancer cells with acquired resistance to zoledronic acid. |
| Q33638286 | Anti-cancer potential of MAPK pathway inhibition in paragangliomas-effect of different statins on mouse pheochromocytoma cells |
| Q27011650 | Beyond the NLRP3 inflammasome: autoinflammatory diseases reach adolescence |
| Q37087037 | Bisphosphonate Induces Osteonecrosis of the Jaw in Diabetic Mice via NLRP3/Caspase-1-Dependent IL-1β Mechanism |
| Q85643235 | Bisphosphonates inhibit cell functions of HUVECs, fibroblasts and osteogenic cells via inhibition of protein geranylgeranylation |
| Q28539314 | Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis |
| Q35335391 | Chemically induced mouse liver tumors are resistant to treatment with atorvastatin |
| Q58750511 | Cholesterol as an Endogenous ERRα Agonist: A New Perspective to Cancer Treatment |
| Q92614318 | Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth |
| Q40207403 | Cytokine-mediated activation of human ex vivo-expanded Vγ9Vδ2 T cells. |
| Q92860259 | Delineation of cell death mechanisms induced by synergistic effects of statins and erlotinib in non-small cell lung cancer cell (NSCLC) lines |
| Q41826396 | Design and synthesis of non-hydrolyzable homoisoprenoid α-monofluorophosphonate inhibitors of PPAPDC family integral membrane lipid phosphatases |
| Q37384979 | Downregulation of CXCR4 Expression and Functionality After Zoledronate Exposure in Canine Osteosarcoma |
| Q34574121 | Drug repurposing screen reveals FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that block Cryptosporidium parvum growth |
| Q37221691 | Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer |
| Q57191805 | Editorial: Drug Repositioning: Current Advances and Future Perspectives |
| Q37015751 | Effect of Lipophilic and Hydrophilic Statins on Breast Cancer Risk in Thai Women: A Cross-sectional Study |
| Q37189557 | Efficient use of exogenous isoprenols for protein isoprenylation by MDA-MB-231 cells is regulated independently of the mevalonate pathway |
| Q90966679 | Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI |
| Q40225671 | Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study |
| Q61449270 | Immunohistochemical Labeling of Low-Density Lipoprotein Receptor and Scavenger Receptor Class B Type 1 Are Increased in Canine Lymphoma |
| Q38968601 | In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells |
| Q87518258 | In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes |
| Q52593223 | Inefficient HIV-1 trans infection of CD4+ T cells by macrophages from HIV-1 nonprogressors is associated with altered membrane cholesterol and DC-SIGN. |
| Q38957404 | Inhibition of autophagy augments apoptosis in human oral squamous cell carcinoma under nutrient depletion |
| Q36021018 | Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo |
| Q38624909 | Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells |
| Q38571156 | Interleukin-6 as an emerging regulator of renal cell cancer |
| Q41456624 | KRASG12D expression in lung-resident myeloid cells promotes pulmonary LCH-like neoplasm sensitive to statin treatment |
| Q45943224 | MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells. |
| Q47105437 | Mevalonate Metabolism in Immuno-Oncology |
| Q46592108 | Mevalonate metabolism governs cancer immune surveillance. |
| Q92935110 | Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer |
| Q21245491 | Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugs |
| Q33716678 | Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans |
| Q44081924 | Plant sterol feeding induces tumor formation and alters sterol metabolism in the intestine of Apc(Min) mice |
| Q38823772 | Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. |
| Q38758048 | Recent Advances in the Development of Mammalian Geranylgeranyl Diphosphate Synthase Inhibitors. |
| Q47836415 | Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines |
| Q97426034 | Regulation of Autophagy Progress via Lysosomal Depletion by Fluvastatin Nanoparticle Treatment in Breast Cancer Cells |
| Q39322285 | Regulation of Metabolic Activity by p53. |
| Q36544608 | Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells |
| Q36557448 | Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. |
| Q34729901 | Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway |
| Q89531647 | Splice switching an oncogenic ratio of SmgGDS isoforms as a strategy to diminish malignancy |
| Q36993452 | Statin Use and Its Impact on Survival in Pancreatic Cancer Patients |
| Q86387770 | Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities |
| Q49835350 | Statin use and pancreatic cancer risk in two prospective cohort studies. |
| Q86695109 | Statin use and peripheral blood progenitor cells mobilization in patients with multiple myeloma |
| Q34757109 | Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma |
| Q39317705 | Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study |
| Q37119810 | Statins and Breast Cancer: Future Directions in Chemoprevention |
| Q57105348 | Statins: a role in breast cancer therapy? |
| Q40953833 | Stress-related and homeostatic cytokines regulate Vγ9Vδ2 T-cell surveillance of mevalonate metabolism. |
| Q48675160 | Successful Treatment of Recurrent Li-Fraumeni Syndrome-related Choroid Plexus Carcinoma |
| Q38398684 | T lymphocyte regulation by mevalonate metabolism. |
| Q39455228 | Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial |
| Q34507114 | Targeting cholesterol synthesis increases chemoimmuno-sensitivity in chronic lymphocytic leukemia cells |
| Q37734257 | Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease |
| Q55195973 | Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma. |
| Q38608866 | The Gut-Liver-Lung Axis. Modulation of the Innate Immune Response and Its Possible Role in Chronic Obstructive Pulmonary Disease |
| Q37396993 | The Primary Effect on the Proteome of ARID1A-mutated Ovarian Clear Cell Carcinoma is Downregulation of the Mevalonate Pathway at the Post-transcriptional Level. |
| Q41380085 | The association of statin therapy with clinicopathologic outcomes and survival among patients with localized renal cell carcinoma undergoing nephrectomy. |
| Q57204754 | The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation |
| Q47296038 | The interplay between mutant p53 and the mevalonate pathway |
| Q38832228 | The isoprenoid derivative N6 -benzyladenosine CM223 exerts antitumor effects in glioma patient-derived primary cells through the mevalonate pathway. |
| Q38149124 | The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics |
| Q64242253 | The role of cholesterol metabolism in cancer |
| Q39201898 | The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy |
| Q35915762 | Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again |
| Q48235186 | Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine |
| Q40553571 | Transcriptional Profiling Reveals a Common Metabolic Program in High-Risk Human Neuroblastoma and Mouse Neuroblastoma Sphere-Forming Cells |
| Q38390100 | γδ T cell therapy for the treatment of non-small cell lung cancer. |
Search more.